Crossmark

An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and <i>in silico</i> simulations of enteric hyperoxaluria

Crossref DOI link: https://doi.org/10.15252/msb.202110539

Published Online: 2022-03-07

Published Print: 2022-03

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Lubkowicz, David https://orcid.org/0000-0002-1012-4811
Horvath, Nicholas G https://orcid.org/0000-0002-2763-8368
James, Michael J

Cantarella, Pasquale

Renaud, Lauren https://orcid.org/0000-0003-2928-9285
Bergeron, Christopher G

Shmueli, Ron B

Anderson, Cami

Gao, Jian‐Rong

Kurtz, Caroline B

Perreault, Mylene

Charbonneau, Mark R

Isabella, Vincent M https://orcid.org/0000-0002-5849-3149
Hava, David L https://orcid.org/0000-0002-9200-1566
License Information

Version of Record valid from 2022-03-07
More Information

Publication History

Received: 2021-06-29

Accepted: 2022-01-31

Published: 2022-03-07